Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials.
about
One more stem cell niche: how the sensitivity of chronic myeloid leukemia cells to imatinib mesylate is modulated within a "hypoxic" environment.Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment.ChiTaRS: a database of human, mouse and fruit fly chimeric transcripts and RNA-sequencing data.ChiTaRS 2.1--an improved database of the chimeric transcripts and RNA-seq data with novel sense-antisense chimeric RNA transcriptsVariable behavior of iPSCs derived from CML patients for response to TKI and hematopoietic differentiation.The metabolically-modulated stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy.ChimeRScope: a novel alignment-free algorithm for fusion transcript prediction using paired-end RNA-Seq data.A Review of Mathematical Models for Leukemia and LymphomaNCLscan: accurate identification of non-co-linear transcripts (fusion, trans-splicing and circular RNA) with a good balance between sensitivity and precisionTargeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.Salarin C inhibits the maintenance of chronic myeloid leukemia progenitor cells.Concise Review: Stem Cell Population Biology: Insights from Hematopoiesis.Long-term molecular remission with persistence of BCR-ABL1-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia-positive ALL.The Leukemic Stem Cell Niche: Adaptation to "Hypoxia" versus Oncogene Addiction.
P2860
Q27692583-87AB8447-587C-4FC0-8E9A-5C55948BDC05Q30251765-A04A393E-94AC-41BA-88E2-A37CAC26BD0FQ30577119-B216C23F-464F-4A82-A9E8-7F3219EB2206Q30870920-91C6D68E-BC04-4DBF-9670-8B61A39B8A0FQ34994180-DAA24670-B02D-48F9-A4B0-428DFA2D7FDFQ36182260-2D7FA531-C5B5-4CEB-846B-40138DA95E2DQ36363386-28DDAAA0-54FA-4B5D-ADC2-95017C3D7A71Q36423882-2ED32D3C-3E3D-4B6D-883B-DD420C43EEDAQ36588864-E25A59F6-8534-4D5C-BECC-FCCACCE9D0D2Q36697774-93D2ABB4-6076-4CFF-9811-E016CD4EC437Q38842352-E04F4A9E-724A-4746-825E-C0BB38D5098AQ38965156-0E8F78C6-4380-4885-AC20-316D8C76A993Q46446491-11B42599-A9A5-4F07-88DF-08CAC7BD4055Q47143906-4072A259-8F22-410C-AEFD-22F8C5E6EAF2
P2860
Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Selection pressure exerted by ...... atinib discontinuation trials.
@en
type
label
Selection pressure exerted by ...... atinib discontinuation trials.
@en
prefLabel
Selection pressure exerted by ...... atinib discontinuation trials.
@en
P2093
P2860
P1433
P1476
Selection pressure exerted by ...... atinib discontinuation trials.
@en
P2093
Franziska Michor
François-Xavier Mahon
Jasmine Foo
Joëlle Guilhot
Mithat Gönen
P2860
P304
P356
10.3324/HAEMATOL.2012.062844
P50
P577
2012-03-14T00:00:00Z